165 related articles for article (PubMed ID: 38342377)
1. MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy.
Kula J; Kuter KZ
Neuropharmacology; 2024 May; 249():109865. PubMed ID: 38342377
[TBL] [Abstract][Full Text] [Related]
2. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment.
Fanning S; Haque A; Imberdis T; Baru V; Barrasa MI; Nuber S; Termine D; Ramalingam N; Ho GPH; Noble T; Sandoe J; Lou Y; Landgraf D; Freyzon Y; Newby G; Soldner F; Terry-Kantor E; Kim TE; Hofbauer HF; Becuwe M; Jaenisch R; Pincus D; Clish CB; Walther TC; Farese RV; Srinivasan S; Welte MA; Kohlwein SD; Dettmer U; Lindquist S; Selkoe D
Mol Cell; 2019 Mar; 73(5):1001-1014.e8. PubMed ID: 30527540
[TBL] [Abstract][Full Text] [Related]
3. Cell models of lipid-rich α-synuclein aggregation validate known modifiers of α-synuclein biology and identify stearoyl-CoA desaturase.
Imberdis T; Negri J; Ramalingam N; Terry-Kantor E; Ho GPH; Fanning S; Stirtz G; Kim TE; Levy OA; Young-Pearse TL; Selkoe D; Dettmer U
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20760-20769. PubMed ID: 31548371
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis.
Tripathi A; Alnakhala H; Terry-Kantor E; Newman A; Liu L; Imberdis T; Fanning S; Nuber S; Ramalingam N; Selkoe D; Dettmer U
J Neurosci; 2022 Mar; 42(10):2116-2130. PubMed ID: 35086904
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson's Disease.
Tardiff DF; Lucas M; Wrona I; Chang B; Chung CY; Le Bourdonnec B; Rhodes KJ; Scannevin RH
Mol Neurobiol; 2022 Apr; 59(4):2171-2189. PubMed ID: 35060064
[TBL] [Abstract][Full Text] [Related]
6. Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor.
Terry-Kantor E; Tripathi A; Imberdis T; LaVoie ZM; Ho GPH; Selkoe D; Fanning S; Ramalingam N; Dettmer U
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707907
[TBL] [Abstract][Full Text] [Related]
7. Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
Tripathi A; Fanning S; Dettmer U
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053188
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity.
Vincent BM; Tardiff DF; Piotrowski JS; Aron R; Lucas MC; Chung CY; Bacherman H; Chen Y; Pires M; Subramaniam R; Doshi DB; Sadlish H; Raja WK; Solís EJ; Khurana V; Le Bourdonnec B; Scannevin RH; Rhodes KJ
Cell Rep; 2018 Dec; 25(10):2742-2754.e31. PubMed ID: 30517862
[TBL] [Abstract][Full Text] [Related]
9. Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity.
Kim TE; Newman AJ; Imberdis T; Brontesi L; Tripathi A; Ramalingam N; Fanning S; Selkoe D; Dettmer U
Hum Mol Genet; 2021 Nov; 30(23):2332-2346. PubMed ID: 34254125
[TBL] [Abstract][Full Text] [Related]
10. A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α-Synuclein Mice.
Nuber S; Nam AY; Rajsombath MM; Cirka H; Hronowski X; Wang J; Hodgetts K; Kalinichenko LS; Müller CP; Lambrecht V; Winkler J; Weihofen A; Imberdis T; Dettmer U; Fanning S; Selkoe DJ
Ann Neurol; 2021 Jan; 89(1):74-90. PubMed ID: 32996158
[TBL] [Abstract][Full Text] [Related]
11. Vesicle trafficking and lipid metabolism in synucleinopathy.
Fanning S; Selkoe D; Dettmer U
Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
[TBL] [Abstract][Full Text] [Related]
12. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
Molecules; 2020 May; 25(10):. PubMed ID: 32456274
[TBL] [Abstract][Full Text] [Related]
13. Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy.
Vermilyea SC; Christensen A; Meints J; Singh B; Martell-Martínez H; Karim MR; Lee MK
Transl Neurodegener; 2022 Jul; 11(1):34. PubMed ID: 35773715
[TBL] [Abstract][Full Text] [Related]
14. Stearoyl-CoA desaturase 5 (SCD5), a Δ-9 fatty acyl desaturase in search of a function.
Igal RA; Sinner DI
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jan; 1866(1):158840. PubMed ID: 33049404
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
16. [Prion-like Propagation of Pathological α-Synuclein in Vivo].
Masuda-Suzukake M; Hasegawa M
Yakugaku Zasshi; 2019; 139(7):1007-1013. PubMed ID: 31257247
[TBL] [Abstract][Full Text] [Related]
17. Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells.
Scaglia N; Igal RA
J Biol Chem; 2005 Jul; 280(27):25339-49. PubMed ID: 15851470
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
19. Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy.
Fanning S; Cirka H; Thies JL; Jeong J; Niemi SM; Yoon J; Ho GPH; Pacheco JA; Dettmer U; Liu L; Clish CB; Hodgetts KJ; Hutchinson JN; Muratore CR; Caldwell GA; Caldwell KA; Selkoe D
NPJ Parkinsons Dis; 2022 Jun; 8(1):74. PubMed ID: 35680956
[TBL] [Abstract][Full Text] [Related]
20. Interactions of α-synuclein oligomers with lipid membranes.
Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
